<DOC>
	<DOC>NCT01775644</DOC>
	<brief_summary>This observastonal multicenter study will evaluate the differences of progression-free survival in defined subgroups of patients with metastatic colorectal cancer receiving Avastin (bevacizumab). Further, safety and efficacy in daily routine will be assessed. Data will be collected for up to 5 years.</brief_summary>
	<brief_title>An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (Koralle)</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Age &gt;= 18 years Patients with metastatic colorectal cancer where investigators have decided to give a firstline, fluoropyrimidinebased combination therapy with Avastin® according to Summary of Product Characteristics (SmPC) Written and signed informed consent prior to onset of documentation Contraindications for Avastin® according to Summary of Products Characteristics (SmPC)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>